Trial Profile

A Phase 1 Study of IPdR in Combination With Capecitabine and Radiotherapy in Rectal Cancer

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 09 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Capecitabine (Primary) ; Ropidoxuridine (Primary)
Indications Adenocarcinoma; Rectal cancer
Focus Adverse reactions; Biomarker

Most Recent Events

02 Feb 2023 Status changed from recruiting to discontinued.
12 May 2022 Status changed from suspended to recruiting.
21 Apr 2022 The study protocol amended to change frequency of oral ropidoxuridine from twice a day to once a day.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com